How Does Viridian Therapeutics Inc (VRDN) Stack Up Against Its Industry Peers?
Needham has recently reiterated Viridian Therapeutics Inc (VRDN) stock to Buy rating, as announced on September 11, 2024, according to Finviz. Earlier, on June 11, 2024, Wolfe Research had initiated the stock to Outperform, setting a price target of $29. Goldman also initiated Buy rating with a price target of $23. Additionally, Ladenburg Thalmann reduced […]
Analysts Predict a $38 Target for Viridian Therapeutics Inc (VRDN) Stock—What Could Drive It There?
Needham has recently reiterated Viridian Therapeutics Inc (VRDN) stock to Buy rating, as announced on September 11, 2024, according to Finviz. Earlier, on June 11, 2024, Wolfe Research had initiated the stock to Outperform, setting a price target of $29. Goldman also initiated Buy rating with a price target of $23. Additionally, Ladenburg Thalmann reduced […]
Viridian Therapeutics Inc (VRDN) Stock: Unveiling Its Hidden Strengths
Wolfe Research has recently initiated Viridian Therapeutics Inc (VRDN) stock to Outperform rating, as announced on June 11, 2024, according to Finviz. Earlier, on June 6, 2024, Goldman had initiated the stock to Buy, setting a price target of $23. Ladenburg Thalmann also reduced Neutral rating. Additionally, B. Riley Securities reduced Neutral rating on May […]
Viridian Therapeutics Inc (VRDN) Stock: Understanding Its Underlying Value
Wolfe Research has recently initiated Viridian Therapeutics Inc (VRDN) stock to Outperform rating, as announced on June 11, 2024, according to Finviz. Earlier, on June 6, 2024, Goldman had initiated the stock to Buy, setting a price target of $23. Ladenburg Thalmann also reduced Neutral rating. Additionally, B. Riley Securities reduced Neutral rating on May […]
What’s Fueling Viridian Therapeutics Inc (VRDN) Stock’s -6.72% Loss Below Its 200-Day SMA?
Wolfe Research has recently initiated Viridian Therapeutics Inc (VRDN) stock to Outperform rating, as announced on June 11, 2024, according to Finviz. Earlier, on June 6, 2024, Goldman had initiated the stock to Buy, setting a price target of $23. Ladenburg Thalmann also reduced Neutral rating. Additionally, B. Riley Securities reduced Neutral rating on May […]
Why Did Viridian Therapeutics Inc (VRDN) Stock See 17.70% Surge in the Last 90 Days?
Wolfe Research has recently initiated Viridian Therapeutics Inc (VRDN) stock to Outperform, as announced on June 11, 2024 according to Finviz. Earlier, on June 6, 2024, Goldman had initiated the stock to Buy, setting a price target of $23 Ladenburg Thalmann also downgraded from Buy to Neutral rating. Additionally, B. Riley Securities downgraded Neutral rating […]
Why Did Wolfe Research Give Viridian Therapeutics Inc (VRDN) Stock Outperform Rating?
Wolfe Research has recently initiated Viridian Therapeutics Inc (VRDN) stock to Outperform, as announced on June 11, 2024 according to Finviz. Earlier, on June 6, 2024, Goldman had initiated the stock to Buy, setting a price target of $23 Ladenburg Thalmann also downgraded from Buy to Neutral rating. Additionally, B. Riley Securities downgraded Neutral rating […]
Viridian Therapeutics Inc (NASDAQ:VRDN) Stock is trading Above 31.10% From 50-Day SMA
Wolfe Research raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 11, 2024, according to finviz. The stock was downgraded by B. Riley Securities, who disclosed in a research note on May 09, 2024, from Buy to Neutral and set the price objective to […]
What is Viridian Therapeutics Inc’s (VRDN) Stock Real Technical Picture?
Wolfe Research raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 11, 2024, according to finviz. The stock was downgraded by B. Riley Securities, who disclosed in a research note on May 09, 2024, from Buy to Neutral and set the price objective to […]
Analysts Rating: Viridian Therapeutics Inc (NASDAQ:VRDN) Stock Won “an Outperform” Rating From Wolfe Research
Wolfe Research raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 11, 2024, according to finviz. The stock was downgraded by B. Riley Securities, who disclosed in a research note on May 09, 2024, from Buy to Neutral and set the price objective to […]
